OptiScan Revenue and Competitors

Mulgrave,

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • OptiScan's estimated annual revenue is currently $7.3M per year.(i)
  • OptiScan's estimated revenue per employee is $251,000

Employee Data

  • OptiScan has 29 Employees.(i)
  • OptiScan grew their employee count by 4% last year.

OptiScan's People

NameTitleEmail/Phone
1
Finance Officer & Administrative CoordinatorReveal Email/Phone
2
Electronic Engineering Core Competency Manager, R&DReveal Email/Phone
3
Engineering ManagerReveal Email/Phone
4
Marketing & Communications ManagerReveal Email/Phone
5
Quality Assurance ManagerReveal Email/Phone
6
EngineerReveal Email/Phone
7
Business Development ManagerReveal Email/Phone
8
Precision assembly technicianReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5M40-18%$10MN/A
#2
$24.8M9929%N/AN/A
#3
$84.1M0N/A$1.2MN/A
#4
$35.6M14230%N/AN/A
#5
$57.5M2296%N/AN/A
#6
$52.7M16825%$129.6MN/A
#7
$21.1M84-3%N/AN/A
#8
$61.2M244-13%N/AN/A
#9
$60.6M19320%$115.5MN/A
#10
$56.2M179-3%$122.9MN/A
Add Company

What Is OptiScan?

Optiscan (ASX:OIL) is a global leader in the development and application of endomicroscopic imaging technologies for medical, translational and pre-clinical markets. Our technology, used by leading research institutions and hospitals in North America, Europe, Asia and Australia enables real-time, in vivo imaging at the cellular level in human and animal tissue. In collaboration with Carl Zeiss Meditec, we are enabling the application of confocal endomicroscopy during brain surgery and together with Pentax Medical released the first-ever human confocal endomicroscopy for gastroenterology. Our recently launched FIVE2 ViewnVivo system builds upon our successful FIVE1 platform with enhanced 3D imaging features enabling virtual biopsies in living, breathing, moving tissue. New applications in the identification of dysplastic and diseased tissue, tumour margins, molecular disease markers, women's health, veterinary and research applications are being developed in association with world-leading institutions. We strive to give health care providers and researchers the highest quality in-vivo microscopic imaging tools available to enable the early detection and management of disease, in order to improve patient outcomes and reduce the high cost of curative medicine.

keywords:N/A

N/A

Total Funding

29

Number of Employees

$7.3M

Revenue (est)

4%

Employee Growth %

N/A

Valuation

N/A

Accelerator

OptiScan News

2022-04-06 - Spotlight On The Montex Stenter At ITM At The Tüyap Fair And ...

The Optiscan balancing system ensures continuous automatic evaluation of the distance between the nozzles and the fabric for highly...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$6.9M359%N/A
#2
$11.2M3517%N/A
#3
$9.8M376%N/A
#4
$8.8M38-7%N/A
#5
$17.2M5812%N/A